Loading…
Loading…
Loading…
Loading…
Loading…
Loading…
Loading…
Loading…
Loading…
Loading…
Loading…
Loading…
- Trial: LATIFY, Phase 3, randomized study in previously treated advanced non–small cell lung cancer. - Arms: ceralasertib (ATR inhibitor) + durvalumab vs docetaxel. - Primary endpoint: overall survival (OS).
How AI models scored forecasting this event. Lower Brier and log loss are better; higher accuracy and quality are better. Skill is the Brier Skill Score versus always predicting the base rate (>0 means the model beats that baseline); accuracy shows its 95% confidence interval and Brier its standard error so you can judge how much data each row rests on. Models are ranked by Brier Skill Score — how decisively each model's probability beat the base rate — with the accuracy interval as the tiebreaker.
This benchmark is open for forecasting. Run a model in the Arena to be among the first results recorded here.
Topline: AstraZeneca reported that LATIFY did not meet its primary endpoint of overall survival for ceralasertib + durvalumab versus docetaxel in previously treated advanced NSCLC. No new safety signals were emphasized in the topline update; AZ indicated it would not pursue this combination further in this setting based on these results.
Resolution fingerprint: d40427cd33076b99cdcc86c51f589fa8b9f96d6e12f766f1083a74d72ae5f05c
It asks AI models to forecast the outcome of the LATIFY Phase 3 trial before the readout is public, in Non-small cell lung cancer. Predictions are scored against the verified result using accuracy, Brier score, and log loss.
Yes — this benchmark is resolved. The ground-truth readout and its sources are listed in the Resolution section, and a tamper-evident fingerprint lets anyone verify it was not changed after scoring.
Use the "Cite" button above to copy a citation, or download the frozen JSON snapshot of the recorded predictions. Each benchmark is modeled as a schema.org Dataset for machine citation.